Albendazole nanocrystals with improved pharmacokinetic performance in mice

Alejandro J Paredes, Sergio Sánchez Bruni, Daniel Allemandi, Carlos Lanusse, Santiago D Palma

Research output: Contribution to journalArticlepeer-review

12 Citations (Scopus)


Aim: Albendazole (ABZ) is a broad-spectrum antiparasitic agent with poor aqueous solubility, which leads to poor/erratic bioavailability and therapeutic failures. Here, we aimed to produce a novel formulation of ABZ nanocrystals (ABZNC) and assess its pharmacokinetic performance in mice. Results/methodology: ABZNC were prepared by high-pressure homogenization and spray-drying processes. Redispersion capacity and solid yield were measured in order to obtain an optimized product. The final particle size was 415.69±7.40 nm and the solid yield was 72.32%. The pharmacokinetic parameters obtained in a mice model for ABZNC were enhanced (p < 0.05) with respect to the control formulation. Conclusion: ABZNC with improved pharmacokinetic behavior were produced by a simple, inexpensive and potentially scalable methodology.
Original languageEnglish
JournalTherapeutic Delivery
Early online date12 Jan 2018
Publication statusPublished - Feb 2018

Fingerprint Dive into the research topics of 'Albendazole nanocrystals with improved pharmacokinetic performance in mice'. Together they form a unique fingerprint.

Cite this